Ziapin2 effectively restores retinal function in preclinical models of retinitis pigmentosa and macular degeneration
A multidisciplinary team of researchers from the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology) and ...
Pharmabiz23h
Health Canada authorizes Roche’s Vabysmo pre-filled syringe for three leading causes of vision loss
Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...
The Pharma Letter1d
Formycon’s Eylea biosimilar wins EC approval
Germany’s Formycon and its licensing partner Klinge Biopharma have announced that the European Commission (EC) has granted ...
PharmiWeb2d
Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
Regulatory ApprovalFormycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / 06:30 CET/CESTThe issuer is solely ...
Knowridge3d
Spotting the first signs of vision loss AMD in older adults
Another common early symptom is blurry or distorted vision. Straight lines, like those on a doorframe or a tiled floor, may ...
ophthalmologytimes4d
Ocugen doses first patient in phase 1 trial of OCU200 for treatment of diabetic macular edema
The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...
GlobalData on MSN4d
Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment
US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...
ophthalmologytimes5d
Outlook Therapeutics completes analysis of 12-week safety and efficacy results of NORSE EIGHT
The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics ...
Outlook falls 10% on ONS-5010 update, warrant inducements
Outlook (OTLK) stock fell 10% after the company said it had completed a study analysis for its drug ONS-5010 and entered into ...
Ocugen announces first patient dosed in Phase 1 OCU200 trial for DME
Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...